| scholarly article | Q13442814 |
| P2093 | author name string | Laura P Stabile | |
| Natalie J Rothenberger | |||
| P2860 | cites work | Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase | Q41661247 |
| Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma | Q42151322 | ||
| Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances | Q42219837 | ||
| TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. | Q42252085 | ||
| Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck | Q42523943 | ||
| Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). | Q42798119 | ||
| E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells | Q43107815 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. | Q43827034 | ||
| Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies | Q43974598 | ||
| Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor | Q45143177 | ||
| Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer | Q46973036 | ||
| Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. | Q47828818 | ||
| Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck | Q47850401 | ||
| Expression of c-Met in laryngeal carcinoma. | Q50892657 | ||
| Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. | Q53479014 | ||
| Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. | Q54017063 | ||
| Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. | Q54315132 | ||
| Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | Q54391771 | ||
| Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. | Q54628931 | ||
| MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. | Q54729777 | ||
| High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. | Q55036309 | ||
| Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma | Q57765077 | ||
| Lymph node prognostic factors in head and neck squamous cell carcinomas | Q72851079 | ||
| Prognostic factors and relative risk for survival in N1-3 oral squamous cell carcinoma: a multivariate analysis using Cox's hazard model | Q73477045 | ||
| Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 | ||
| Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases | Q73911408 | ||
| Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance | Q74287365 | ||
| Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma | Q77303734 | ||
| Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma | Q77765744 | ||
| Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer | Q77948466 | ||
| Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma | Q79790032 | ||
| Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells | Q79815565 | ||
| Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma | Q79987701 | ||
| Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma | Q80421952 | ||
| Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas | Q81168633 | ||
| Molecular cloning and expression of human hepatocyte growth factor | Q24305558 | ||
| Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors | Q24339620 | ||
| Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death | Q24610879 | ||
| Immunotherapy for head and neck squamous cell carcinoma | Q26739850 | ||
| Global trends of lung cancer mortality and smoking prevalence | Q26784117 | ||
| Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer | Q26852215 | ||
| Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases | Q27657708 | ||
| Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent | Q27679191 | ||
| Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study | Q27851592 | ||
| Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies | Q27852005 | ||
| Crizotinib in ROS1-rearranged non-small-cell lung cancer. | Q27853075 | ||
| Epithelial-mesenchymal transitions in tumour progression | Q27860487 | ||
| Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells | Q28140678 | ||
| The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells | Q28143877 | ||
| Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas | Q28182566 | ||
| c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors | Q28295039 | ||
| Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis | Q28295920 | ||
| Case-control study of human papillomavirus and oropharyngeal cancer | Q28301695 | ||
| Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor | Q28307227 | ||
| Scatter factor/hepatocyte growth factor is essential for liver development | Q28504542 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer | Q33682988 | ||
| Matrix metalloproteases in head and neck cancer | Q33863220 | ||
| Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data | Q33873118 | ||
| Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma | Q34085434 | ||
| Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance | Q34161089 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. | Q34419289 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice | Q34627751 | ||
| Scatter-factor and semaphorin receptors: cell signalling for invasive growth | Q34632043 | ||
| c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase | Q34883707 | ||
| Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail | Q34972866 | ||
| The role of epidermal growth factor receptor in head and neck squamous cell carcinoma | Q35065193 | ||
| Epidemiology, staging, and screening of head and neck cancer. | Q35078962 | ||
| Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells | Q35110418 | ||
| HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer | Q35174872 | ||
| TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation | Q35525917 | ||
| Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer | Q36005545 | ||
| E-cadherin expression and prognosis of head and neck squamous cell carcinoma: evidence from 19 published investigations | Q36027644 | ||
| Prognostic value of c-Met expression in oral squamous cell carcinoma | Q36375213 | ||
| c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met | Q36545205 | ||
| Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. | Q36660533 | ||
| Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor | Q36705281 | ||
| Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. | Q36741216 | ||
| Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis | Q36915616 | ||
| Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment | Q36988805 | ||
| HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma | Q36992487 | ||
| A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins | Q37139435 | ||
| MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma | Q37490555 | ||
| Alteration status and prognostic value of MET in head and neck squamous cell carcinoma | Q37514050 | ||
| MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy | Q37597858 | ||
| The role of human papillomavirus infection in head and neck cancers. | Q37799932 | ||
| Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway | Q37895099 | ||
| Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature | Q38030130 | ||
| Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer | Q38089600 | ||
| Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. | Q38208571 | ||
| The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck | Q38211236 | ||
| Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma | Q38322099 | ||
| c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. | Q38392890 | ||
| Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx | Q38450015 | ||
| Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma | Q38512195 | ||
| Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | Q38544333 | ||
| Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study | Q38787080 | ||
| Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. | Q38821826 | ||
| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | Q38849759 | ||
| HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. | Q38883827 | ||
| Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma | Q38916240 | ||
| LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth | Q38955519 | ||
| Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines | Q38956071 | ||
| Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. | Q38959172 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Preclinical models in HNSCC: A comprehensive review | Q39097398 | ||
| EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas | Q39111192 | ||
| Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models | Q39144705 | ||
| HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics | Q39214964 | ||
| EMT and tumor metastasis | Q39216425 | ||
| Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. | Q39442106 | ||
| Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation | Q39566894 | ||
| Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. | Q39674871 | ||
| ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. | Q39702478 | ||
| Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors | Q40146257 | ||
| Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma | Q40172206 | ||
| Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion | Q40698534 | ||
| An orthotopic nude mouse model of oral tongue squamous cell carcinoma. | Q40756187 | ||
| Roles of HGF as a pleiotropic factor in organ regeneration. | Q40870023 | ||
| Three-dimensional cell cultures: from molecular mechanisms to clinical applications | Q41633372 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | head and neck cancer | Q1783924 |
| head and neck carcinoma | Q18554836 | ||
| neck cancer | Q18966654 | ||
| P577 | publication date | 2017-04-24 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment | |
| P478 | volume | 9 |
| Q64086042 | Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives |
| Q91902169 | Clinical update on head and neck cancer: molecular biology and ongoing challenges |
| Q49414583 | Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review |
| Q47220671 | Fisetin suppresses malignant proliferation in human oral squamous cell carcinoma through inhibition of Met/Src signaling pathways |
| Q59799184 | Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome |
| Q92697387 | MicroRNA-449b-5p Suppresses Proliferation, Migration, and Invasion of Osteosarcoma by Targeting c-Met |
| Q94546963 | Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization |
| Q89525448 | Tumor immune microenvironment in head and neck cancers |
| Q89739717 | Two miRNA prognostic signatures of head and neck squamous cell carcinoma: A bioinformatic analysis based on the TCGA dataset |
Search more.